688488 艾迪药业
午间休市 05-06 11:29:49
资讯
新帖
简况
创新药盈利尚早 艾迪药业加码尿激酶业务
中国经营网 · 04-27
创新药盈利尚早 艾迪药业加码尿激酶业务
艾迪药业： 公司已于2024年4月26日发布2024年第一季度报告，具体请查阅公告相关内容
证券之星 · 04-26
艾迪药业： 公司已于2024年4月26日发布2024年第一季度报告，具体请查阅公告相关内容
艾迪药业(688488)3月31日股东户数0.82万户，较上期减少18.8%
证券之星 · 04-26
艾迪药业(688488)3月31日股东户数0.82万户，较上期减少18.8%
艾迪药业大幅下跌 Q1营收同比减少17.52%
智选洞察 · 04-26
艾迪药业大幅下跌 Q1营收同比减少17.52%
艾迪药业：2024年第一季度净利润约-1361万元
每日经济新闻 · 04-25
艾迪药业：2024年第一季度净利润约-1361万元
艾迪药业(688488.SH)发一季度业绩，净亏损1360.69万元
智通财经 · 04-25
艾迪药业(688488.SH)发一季度业绩，净亏损1360.69万元
艾迪药业(688488)：国内抗艾先驱 创新转型进入收获期
广发证券股份有... · 04-25
艾迪药业(688488)：国内抗艾先驱 创新转型进入收获期
艾迪药业（688488）4月24日主力资金净买入198.08万元
证券之星 · 04-25
艾迪药业（688488）4月24日主力资金净买入198.08万元
北向资金4月23日净卖出艾迪药业14.82万股 连续3日减持
自选股智能写手 · 04-24
北向资金4月23日净卖出艾迪药业14.82万股 连续3日减持
艾迪药业(688488)2023年年度报告点评：营收同比大幅增长 HIV新药业务进展迅速
东北证券股份有... · 04-23
艾迪药业(688488)2023年年度报告点评：营收同比大幅增长 HIV新药业务进展迅速
艾迪药业04月23日获主力加仓932万元 环比增加461.45%
自选股智能写手 · 04-23
艾迪药业04月23日获主力加仓932万元 环比增加461.45%
艾迪药业（688488）4月22日主力资金净买入195.21万元
证券之星 · 04-23
艾迪药业（688488）4月22日主力资金净买入195.21万元
生物制品行业盘中拉升，艾迪药业涨5.51%
自选股智能写手 · 04-22
生物制品行业盘中拉升，艾迪药业涨5.51%
艾迪药业大幅上涨 科创金融支持生物医药专利转化
智选洞察 · 04-22
艾迪药业大幅上涨 科创金融支持生物医药专利转化
艾迪药业04月19日主力资金流出38万元 连续5日减仓
自选股智能写手 · 04-19
艾迪药业04月19日主力资金流出38万元 连续5日减仓
大客户续约存不确定性 艾迪药业能否靠抗艾创新药扭亏|财报金选
和讯财经 · 04-18
大客户续约存不确定性 艾迪药业能否靠抗艾创新药扭亏|财报金选
华安证券给予艾迪药业买入评级 季度改善符合预期 展望医保首年销售放量
每日经济新闻 · 04-17
华安证券给予艾迪药业买入评级 季度改善符合预期 展望医保首年销售放量
艾迪药业(688488)：HIV新药艾诺米替片纳入医保快速放量
西南证券股份有... · 04-17
艾迪药业(688488)：HIV新药艾诺米替片纳入医保快速放量
艾迪药业04月17日遭主力抛售701万元 环比增加407.97%
自选股智能写手 · 04-17
艾迪药业04月17日遭主力抛售701万元 环比增加407.97%
艾迪药业：23年营收增长68.44% 未来仍将聚焦抗艾及人源蛋白领域
挖贝网 · 04-17
艾迪药业：23年营收增长68.44% 未来仍将聚焦抗艾及人源蛋白领域
加载更多
公司概况
公司名称：
江苏艾迪药业股份有限公司
所属行业：
其他制造业
上市日期：
2020-07-20
主营业务：
江苏艾迪药业股份有限公司主营业务以为HIV为主的抗病毒业务及人源蛋白业务。主要产品有乌司他丁、尤瑞克林、尿激酶等人源蛋白产品以及蜡样芽孢杆菌片、番泻叶颗粒、头孢拉定胶囊等制剂。公司荣获“2023年度扬州民营企业创新20强”、荣登“2022年度扬州市创新型企业50强”名单及“2022年度中国小分子药物企业创新力TOP30排行榜”。
发行价格：
13.99
{"stockData":{"symbol":"688488","market":"SH","secType":"STK","nameCN":"艾迪药业","latestPrice":15.79,"timestamp":1714966189000,"preClose":14.78,"halted":0,"volume":4629251,"delay":0,"floatShares":421000000,"shares":421000000,"eps":-0.2143,"marketStatus":"午间休市","marketStatusCode":3,"change":1.01,"latestTime":"05-06 11:29:49","open":14.82,"high":15.9,"low":14.81,"amount":72029300,"amplitude":0.0737,"askPrice":15.79,"askSize":0,"bidPrice":15.78,"bidSize":12,"shortable":0,"etf":0,"ttmEps":-0.2143,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714971600000},"adr":0,"adjPreClose":14.78,"symbolType":"stock_kcb","openAndCloseTimeList":[[1714959000000,1714966200000],[1714971600000,1714978800000]],"highLimit":16.26,"lowLimit":13.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":420782808,"pbRate":5.58,"roa":"--","roe":"--","epsLYR":-0.18,"committee":-0.044944,"marketValue":6644000000,"floatMarketCap":6644000000,"peRate":-73.681752,"changeRate":0.0683,"turnoverRate":0.011,"status":0},"requestUrl":"/m/hq/s/688488","defaultTab":"news","newsList":[{"id":"2430358447","title":"创新药盈利尚早 艾迪药业加码尿激酶业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2430358447","media":"中国经营网","top":-1,"share":"https://www.laohu8.com/m/news/2430358447?lang=zh_cn&edition=full","pubTime":"2024-04-27 03:50","pubTimestamp":1714161011,"startTime":"0","endTime":"0","summary":"公告显示，艾迪药业拟以现金收购南大药业31.161%的股权。在交易完成后，艾迪药业对该标的持股超过50%，南大药业届时将纳入艾迪药业财务报表合并范围，但此次交易价格未定。年报显示，2023年艾迪药业向南大药业销售尿激酶粗品约1.62亿元，约占公司人源蛋白业务整体收入的62%，更为公司贡献近四成的总营收。交易完成后，艾迪药业成为南大药业第二大股东。艾迪药业彼时在问询答复函中表示。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404270359548b585db5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404270359548b585db5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430227597","title":"艾迪药业：\n公司已于2024年4月26日发布2024年第一季度报告，具体请查阅公告相关内容","url":"https://stock-news.laohu8.com/highlight/detail?id=2430227597","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430227597?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:02","pubTimestamp":1714129336,"startTime":"0","endTime":"0","summary":"证券之星消息，艾迪药业04月26日在投资者关系平台上答复投资者关心的问题。公司已于2024年4月26日发布2024年第一季度报告，具体请查阅公告相关内容。目前该交易仍处于初步筹划阶段，后续如有进一步进展公司会根据相关法律法规要求履行信息披露义务。感谢您对公司关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600047567.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430283782","title":"艾迪药业(688488)3月31日股东户数0.82万户，较上期减少18.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430283782","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430283782?lang=zh_cn&edition=full","pubTime":"2024-04-26 17:16","pubTimestamp":1714122972,"startTime":"0","endTime":"0","summary":"证券之星消息，近日艾迪药业披露，截至2024年3月31日公司股东户数为8237.0户，较12月31日减少1907.0户，减幅为18.8%。在生物制品行业个股中，艾迪药业股东户数低于行业平均水平，截至3月31日，生物制品行业平均股东户数为3.36万户。从股价来看，2023年12月31日至2024年3月31日，艾迪药业区间涨幅为28.62%，在此期间股东户数减少1907.0户，减幅为18.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600039964.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430968522","title":"艾迪药业大幅下跌 Q1营收同比减少17.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430968522","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2430968522?lang=zh_cn&edition=full","pubTime":"2024-04-26 09:50","pubTimestamp":1714096248,"startTime":"0","endTime":"0","summary":"消息解读艾迪药业2024年第一季度营收约9289万元，同比减少17.52%。报告期内公司实现营业收入9289.40万元，同比减少17.52%。北向资金方面，艾迪药业04月25日获得北向资金减持5.45万股连续5日减持，截至04月25日，北向资金当前共持有艾迪药业90.31万股，市值1353万元，持股占流通股比为0.21%。最新财报显示，今年一季报，艾迪药业实现营业收入9,289.40万元，同比减少17.52%，净利润为-1,360.69万元，同比减少2898.79%，基本每股收益为-0.03元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261009107a55ec1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261009107a55ec1b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430382472","title":"艾迪药业：2024年第一季度净利润约-1361万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430382472","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430382472?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:46","pubTimestamp":1714052791,"startTime":"0","endTime":"0","summary":"艾迪药业（SH 688488，收盘价：15.79元）4月25日晚间发布一季度业绩公告称，2024年第一季度营收约9289万元，同比减少17.52%；归属于上市公司股东的净利润亏损约1361万元；基本每股收益亏损0.03元。艾迪药业的董事长是傅和亮，男，63岁，学历背景为博士；总裁是张杰，男，54岁，学历背景为硕士。截至发稿，艾迪药业市值为66亿元。文章来源：每日经济新闻原标题：艾迪药业：2024年第一季度净利润约-1361万元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042523211387afcd52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042523211387afcd52&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430406866","title":"艾迪药业(688488.SH)发一季度业绩，净亏损1360.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430406866","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430406866?lang=zh_cn&edition=full","pubTime":"2024-04-25 19:20","pubTimestamp":1714044038,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾迪药业(688488.SH)发布2024年第一季度报告，报告期内公司实现营业收入9289.40万元，同比减少17.52%;归属于上市公司股东的净亏损1360.69万元;归属于上市公司股东扣除非经常性损益净亏损1737.97万元;基本每股亏损0.03元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1110304.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430465282","title":"艾迪药业(688488)：国内抗艾先驱 创新转型进入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2430465282","media":"广发证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2430465282?lang=zh_cn&edition=full","pubTime":"2024-04-25 08:23","pubTimestamp":1714004591,"startTime":"0","endTime":"0","summary":"HIV 治疗领域不断迭代，国内抗艾市场快速增长。近年来，随着众多进口HIV 新药，尤其是复方单片制剂在国内上市并被纳入医保，由于单片方案在疗效、安全性、便捷性等方面存在着较大优势，推动我国HIV 治疗市场快速增长。公司HIV 新药处于商业化早期快速放量阶段，23 年实现销售收入7,358 万元，同比增长119.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042508231787acb8cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042508231787acb8cb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430841333","title":"艾迪药业（688488）4月24日主力资金净买入198.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430841333","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430841333?lang=zh_cn&edition=full","pubTime":"2024-04-25 07:51","pubTimestamp":1714002681,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月24日收盘，艾迪药业报收于15.38元，下跌1.6%，换手率0.45%，成交量1.89万手，成交额2914.56万元。近5日资金流向一览见下表：艾迪药业融资融券信息显示，融资方面，当日融资买入123.23万元，融资偿还123.91万元，融资净偿还0.68万元。艾迪药业主营业务：专注于医药领域,集药品研发、生产、销售于一体。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500013435.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429524176","title":"北向资金4月23日净卖出艾迪药业14.82万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2429524176","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429524176?lang=zh_cn&edition=full","pubTime":"2024-04-24 09:30","pubTimestamp":1713922233,"startTime":"0","endTime":"0","summary":"4月23日，北向资金减持艾迪药业14.82万股连续3日减持。截止当日收盘，沪股通共持有艾迪药业97.85万股，占流通股0.23%。沪股通减持金额前五个股分别为中国中免、国电南瑞、中国建筑、兆易创新、中国联通。艾迪药业近5个交易日上涨7.05%，沪股通累计减持71.16万股；近20个交易日上涨1.43%，沪股通累计增持42.65万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404240935428b4cb457&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404240935428b4cb457&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429198149","title":"艾迪药业(688488)2023年年度报告点评：营收同比大幅增长 HIV新药业务进展迅速","url":"https://stock-news.laohu8.com/highlight/detail?id=2429198149","media":"东北证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2429198149?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:50","pubTimestamp":1713869426,"startTime":"0","endTime":"0","summary":"事件：近日，公司发布2023 年年度报告。公司2023 年营收同比增速达68.44%，其中人源蛋白业务收入2.60 亿元，药品业务收入1.42 亿元，HIV 新药业务收入0.74 亿元，各业务线均实现高速增长。2023 年亏损实现同比缩减，主要由于主营业务毛利实现同比增加等原因。HIV 新药业务领域具先发优势，进展迅速，医保助力有望不断放量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231850318b4a43f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231850318b4a43f2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429528371","title":"艾迪药业04月23日获主力加仓932万元 环比增加461.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429528371","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429528371?lang=zh_cn&edition=full","pubTime":"2024-04-23 15:19","pubTimestamp":1713856790,"startTime":"0","endTime":"0","summary":"04月23日, 艾迪药业股价涨2.16%，报收15.63元，成交金额7201万元，换手率1.11%，振幅6.54%，量比0.85。艾迪药业今日主力资金净流入932万元，上一交易日主力净流入166万元，今日环比增加461.45%。|04月23日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|利仁科技|5.46%|#|蓝海华腾|4.81%|#|建研设计|3.90%|#|丰立智能|3.83%|#|彩虹集团|3.55%|#|科安达|3.36%|#|天禾股份|3.30%|#|招标股份|3.18%|#|迈赫股份|2.78%|#|洪通燃气|2.51%|艾迪药业所在的生物制品行业，今日主力净流入2.74亿元，行业排名6/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042315374587a5081e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042315374587a5081e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429183536","title":"艾迪药业（688488）4月22日主力资金净买入195.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429183536","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429183536?lang=zh_cn&edition=full","pubTime":"2024-04-23 07:41","pubTimestamp":1713829296,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月22日收盘，艾迪药业报收于15.3元，上涨6.77%，换手率1.37%，成交量5.77万手，成交额8672.24万元。近5日资金流向一览见下表：艾迪药业融资融券信息显示，融资方面，当日融资买入301.99万元，融资偿还255.87万元，融资净买入46.12万元。艾迪药业主营业务：专注于医药领域,集药品研发、生产、销售于一体。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300010885.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429644369","title":"生物制品行业盘中拉升，艾迪药业涨5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429644369","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429644369?lang=zh_cn&edition=full","pubTime":"2024-04-22 10:07","pubTimestamp":1713751620,"startTime":"0","endTime":"0","summary":"04月22日，生物制品行业盘中拉升，截至10点06分，生物制品行业整体指数上涨1.15%，报6626.840点。从个股上来看，该行业的成分股中，艾迪药业涨5.51%，我武生物、西藏药业、凯因科技涨幅居前。从资金上来看，截止发稿，生物制品行业主力净流入为2207.97万，其中西藏药业受到资金热捧，主力净流入1363.09万；拉长时间线来看，该板块近20日主力资金净流入-25.67亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042210070087e825f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042210070087e825f5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429964453","title":"艾迪药业大幅上涨 科创金融支持生物医药专利转化","url":"https://stock-news.laohu8.com/highlight/detail?id=2429964453","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2429964453?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:59","pubTimestamp":1713751182,"startTime":"0","endTime":"0","summary":"04月22日，艾迪药业股价大幅上涨，截至09点59分，艾迪药业上涨5.02%，报15.05元/股，成交2841万元，换手率0.46%，振幅5.58%。消息解读近日，全国首个《科创金融支持生物医药高价值专利转化服务指南》团体标准在沪正式发布。资金动向截止发稿，艾迪药业获得主力净流出215万元。北向资金方面，艾迪药业04月19日获得北向资金减持15.86万股，截至04月19日，北向资金当前共持有艾迪药业137.88万股，市值2075万元，持股占流通股比为0.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221002117a545fbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221002117a545fbc&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428682218","title":"艾迪药业04月19日主力资金流出38万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428682218","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428682218?lang=zh_cn&edition=full","pubTime":"2024-04-19 15:20","pubTimestamp":1713511200,"startTime":"0","endTime":"0","summary":"04月19日, 艾迪药业股价涨1.85%，报收14.33元，成交金额5529万元，换手率0.93%，振幅5.33%，量比0.71。艾迪药业今日主力资金净流出38万元，连续5日净流出，上一交易日主力净流出541万元，今日环比减少92.98%。该股近5个交易日下跌11.32%，主力资金累计净流出1649万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出996万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191541138b39f8f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191541138b39f8f9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428585470","title":"大客户续约存不确定性 艾迪药业能否靠抗艾创新药扭亏|财报金选","url":"https://stock-news.laohu8.com/highlight/detail?id=2428585470","media":"和讯财经","top":-1,"share":"https://www.laohu8.com/m/news/2428585470?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:54","pubTimestamp":1713405246,"startTime":"0","endTime":"0","summary":"4月16日，艾迪药业披露2023年年报。自上市以来，艾迪药业该部分业务销售便倚重天普生化，其采购需求对公司经营业绩影响较大。艾迪药业表示，截至2023年底，公司抗艾创新药医院覆盖范围稳步扩大，新增患者增速明显，服药粘性提高。自上市以来，艾迪药业便一直面临盈利压力，截至2023年，已连续亏损四年。对于艾迪药业来说，目前已有两款创新药实现商业化，能否依靠自主研发创新药实现盈利，和讯财经将保持关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418095416878c9a43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418095416878c9a43&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428390747","title":"华安证券给予艾迪药业买入评级 季度改善符合预期 展望医保首年销售放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2428390747","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2428390747?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:55","pubTimestamp":1713344121,"startTime":"0","endTime":"0","summary":"华安证券04月17日发布研报称，给予艾迪药业（688488.SH，最新价：14.58元）买入评级。评级理由主要包括：1）销售Q4环比季度改善明显，ACC008销售提升显著；2）公司团队全新架构，直营+招商模式扩大渗透市场；3）HIV在售药物扩大进院，整合酶抑制剂临床推进中。风险提示：艾诺韦林、艾诺米替销售浮动的风险；人源蛋白订单持续性不达预期的风险；医保政策不确定性的风险等。AI点评：艾迪药业近一个月获得1份券商研报关注。文章来源：每日经济新闻原标题：华安证券给予艾迪药业买入评级，季度改善符合预期，展望医保首年销售放量","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171819098b2e6b3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171819098b2e6b3e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428393855","title":"艾迪药业(688488)：HIV新药艾诺米替片纳入医保快速放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2428393855","media":"西南证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2428393855?lang=zh_cn&edition=full","pubTime":"2024-04-17 15:51","pubTimestamp":1713340281,"startTime":"0","endTime":"0","summary":"艾诺米替片纳入医保快速放量，患者积累呈“滚雪球”式增长。两款抗艾滋病1类创新药艾诺韦林片、艾诺米替片已获批上市并进入商业化阶段。HIV整合酶抑制剂ACC017片目前境内生产药品临床试验申请获得批准，进入Ⅰ期临床试验。盈利预测：公司是抗HIV 新药排头兵，首个国产三联单片复方抗艾滋病1 类新药疗效和安全性优异，纳入医保有望快速放量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171551258787e3a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171551258787e3a0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428367373","title":"艾迪药业04月17日遭主力抛售701万元 环比增加407.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428367373","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428367373?lang=zh_cn&edition=full","pubTime":"2024-04-17 15:19","pubTimestamp":1713338371,"startTime":"0","endTime":"0","summary":"04月17日, 艾迪药业股价跌0.14%，报收14.58元，成交金额8011万元，换手率1.28%，振幅7.33%，量比1.15。艾迪药业今日主力资金净流出701万元，连续3日净流出，上一交易日主力净流出138万元，今日环比增加407.97%。|04月17日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|永兴股份|7.11%|#|中电电机|5.40%|#|百通能源|4.23%|#|金盾股份|3.87%|#|中信海直|3.67%|#|苏州规划|3.39%|#|佳云科技|3.23%|#|中捷精工|3.01%|#|肇民科技|2.64%|#|魅视科技|2.56%|艾迪药业所在的生物制品行业，今日主力净流入1.35亿元，行业排名64/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171533218b2dd058&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171533218b2dd058&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428317783","title":"艾迪药业：23年营收增长68.44% 未来仍将聚焦抗艾及人源蛋白领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2428317783","media":"挖贝网","top":-1,"share":"https://www.laohu8.com/m/news/2428317783?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:31","pubTimestamp":1713317475,"startTime":"0","endTime":"0","summary":"4月15日晚间，艾迪药业发布2023年年度报告。数据显示，公司23年实现营业收入41,136.38万元，同比增长68.44%；公司实现归属于上市公司股东的净利润为-7,606.95万元，同比减少亏损38.70%。其中，公司HIV新药合计实现收入7,357.88万元，同比增长119.67%；实现人源蛋白粗品实现收入25,975.39万元，较去年同期增长81.11%。公司表示，2024年公司的战略发展目标仍将聚焦于抗HIV领域及人源蛋白领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170932278b2ca1d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170932278b2ca1d7&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-07-20","address":"江苏省扬州市邗江区新甘泉西路69号","stockEarnings":[{"period":"1week","weight":-0.0544},{"period":"1month","weight":-0.0814},{"period":"3month","weight":0.3813},{"period":"6month","weight":0.144},{"period":"1year","weight":0.0068},{"period":"ytd","weight":0.1815}],"companyName":"江苏艾迪药业股份有限公司","boardCode":"AI0041","perCapita":"51084股","boardName":"其他制造业","registeredCapital":"42078万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":" 江苏艾迪药业股份有限公司主营业务以为HIV为主的抗病毒业务及人源蛋白业务。主要产品有乌司他丁、尤瑞克林、尿激酶等人源蛋白产品以及蜡样芽孢杆菌片、番泻叶颗粒、头孢拉定胶囊等制剂。公司荣获“2023年度扬州民营企业创新20强”、荣登“2022年度扬州市创新型企业50强”名单及“2022年度中国小分子药物企业创新力TOP30排行榜”。","serverTime":1714970014248,"listedPrice":13.99,"stockholders":"8237人(较上一季度减少18.80%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾迪药业,688488,艾迪药业股票,艾迪药业股票老虎,艾迪药业股票老虎国际,艾迪药业行情,艾迪药业股票行情,艾迪药业股价,艾迪药业股市,艾迪药业股票价格,艾迪药业股票交易,艾迪药业股票购买,艾迪药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}